This segment focuses on the research and development of novel therapeutics for cardiometabolic diseases, including obesity and related conditions. Research activities include preclinical studies and clinical trials evaluating compounds like DA-1726, a long-acting formulation for obesity treatment. The company utilizes advanced methodologies to assess efficacy, safety, and tolerability. The patient impact is significant, as these therapies aim to address the growing global burden of obesity and related metabolic disorders. Market positioning involves strategic collaborations, such as the joint research agreement with Dong-A ST and ImmunoForge. Future opportunities include expanding the pipeline and securing regulatory approvals. Clinical trials are a key aspect of this segment, with ongoing Phase 1 studies for DA-1726. Partnerships with research institutions and pharmaceutical companies are crucial for advancing these programs.

This segment is dedicated to developing treatments for neurodegenerative diseases, such as cognitive impairment. The primary focus is on NB-02, a therapeutic candidate designed to address the progression of neurodegenerative diseases. Research and development efforts include preclinical studies, clinical trials, and intellectual property protection through patent filings. The company utilizes advanced methodologies to understand the mechanisms of neurodegeneration and develop targeted therapies. The patient impact is substantial, as these therapies aim to improve cognitive function and modify disease progression. Market positioning involves securing intellectual property rights and seeking strategic partnerships. Future opportunities include expanding the pipeline and securing regulatory approvals. Clinical trials are a key aspect of this segment, with ongoing studies to evaluate the safety and efficacy of NB-02. Partnerships with research institutions and pharmaceutical companies are crucial for advancing these programs.

This segment focuses on the development of therapies for COVID-19. The primary focus is on ANA001, an oral niclosamide formulation, which has completed Phase 2 clinical trials. Research and development activities include clinical trials to assess the efficacy and safety of ANA001 in treating patients with moderate COVID-19. The company utilizes advanced methodologies to evaluate the antiviral effects and clinical outcomes. The patient impact is significant, as these therapies aim to provide effective treatment options for COVID-19. Market positioning involves seeking regulatory approvals and potential partnerships for commercialization. Future opportunities include expanding the application of ANA001 and developing new antiviral therapies. Clinical trials are a key aspect of this segment, with ongoing studies to evaluate the efficacy and safety of ANA001. Partnerships with research institutions and pharmaceutical companies are crucial for advancing these programs.